Zoryve® (roflumilast) – Expanded indication
October 6, 2023 - Arcutis Biotherapeutics announced the FDA approval of Zoryve (roflumilast), for the topical treatment of plaque psoriasis, including intertriginous areas, in patients 6 years of age and older.
Download PDF
